A Phase 3 interventional study of Probiotic (Inersan) and Placebo in Chronic Periodontitis, sponsored by CD Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-07-23.
Sponsored by CD Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Chronic Periodontitis with a site in India — 2 open to participants now, 3 under way, none of them phase 3. Chronic Periodontitis · India.
Among the 53 studies in Chronic Periodontitis with a site in India, this one is the 40th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2013, is one of 8 in phase 3, and was the 1st registered.
377 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.
Browse Chronic Periodontitis studies →2 of the 53 studies in Chronic Periodontitis with a site in India are open now. Recruiting first, the newest first:
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 30–50
Postgraduate Institute of Dental Sciences Rohtak · Sites in India
Ages 30–50 · Healthy volunteers
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 25 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 17 · Phase 3 17 · Phase 4 6
First in 2011; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 46 across 307 interventional studies indexed under Chronic Periodontitis.
Median enrollment 53 across the 46 interventional studies, 90 across the 7 observational. Of the 43 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 53 have an industry lead sponsor. The 10 most frequent:
CD Pharma India Pvt. Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
CD Pharma India Pvt. Ltd. has 3 studies filed under Chronic Periodontitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 53 studies in Chronic Periodontitis with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Periodontal disease is a major cause of tooth loss in humans and is one of the most prevalent diseases associated with bone loss. Following bacterial colonization, the gingiva becomes inflamed leading, in some cases, to the destruction of the alveolar bone. Periodontitis has two distinct but interconnected etiologic components, periodontopathic bacteria and host-mediated connective tissue-destructive responses to the causative bacteria and their metabolic products.
A few studies have revealed that probiotic Lactobacillus strains were useful in reducing gingival inflammation and the number of black-pigmented rods, including Porphyromonas gingivalis (Pg), in the saliva and sub-gingival plaque. Concerning periodontal conditions, its shown that application of beneficial bacteria, as an adjunct to scaling and root planing (SRP), can inhibit re-colonization of pathogens in periodontal pockets and reduce bleeding on probing.
The aim of the present study is to evaluate the improvement of periodontal health with probiotic (Inersan) lozenges, used as an adjunct to scaling and root planing [SRP].
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
Drug: Probiotic (Inersan)
Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).
Drug: Placebo
Also known as: Inersan contains not less than 1 billion CFU of Lactobacillus brevis CD2
Also known as: Placebo contains all excipients except the active constituent (Lactobacillus brevis CD2)
Improvement in periodontal indices
Improvement in Periodontal indices, namely, plaque index \[PI\], Gingival index \[GI\], Gingival bleeding index \[GBI\], probing pocket depth \[PPD\] and clinical attachment levels \[CAL\] in both groups
Time frame: 6 weeks, 12 weeks
Microbiological indices
Changes in pathogen (Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), and Prevotella intermedia) levels
Time frame: 6 weeks, 12 weeks
The record gives a start of Jun 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
CD Pharma India Pvt. Ltd.